Recent Finacing
Recent Raise
SanBio develops cell‑based regenerative therapies for neurological disorders, advancing SB623 in Phase 2b stroke and global Phase 2 traumatic‑brain‑injury trials, partnering with Sumitomo Dainippon Pharma and Sunovion.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at SanBio.
